Starting HAART With High CD4 Counts Reduces Incidence of Squamous Cell Anal Cancer
Posted 02-23-2010 at 06:45 PM by admin
Starting HAART With High CD4 Counts Reduces Incidence of Squamous Cell Anal Cancer: Presented at CROI
Doctor's Guide
DGDispatch
By Ed Susman
SAN FRANCISCO -- February 22, 2010 -- Patients with HIV who begin antiretroviral therapy before their CD4-positive cell counts drop below 200 cells/mm3 appear to have significantly reduced risk of developing squamous cell cancer of the anus, researchers said here at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).
"Although the crude incidence of squamous cell cancer of the anus in HIV-infected individuals is higher among those who ever received highly active antiretroviral therapy [HAART], the risk of squamous cell cancer of the anus is significantly lower in patients with re-therapy nadir CD4 counts of 200 or less, and the risk decreases with higher adherence to therapy," said Elizabeth Chiao, MD, Baylor College of Medicine, Houston, Texas.
"Initiating highly active antiretroviral therapy at higher CD4 counts and optimising adherence may decrease the risk of subsequent squamous cell cancer of the anus," she said during her poster presentation on February 19.
Dr. Chiao and colleagues performed a retrospective cohort study utilising data from the Veterans Affairs Immunologic Case Registry from 1987 to 2007, which contains laboratory and pharmacy data, as well as ICD-9 diagnosis codes of all HIV-positive veterans.
"We identified 36,788 individuals in the cohort," she said. "Of these, 20,085 received at least 1 prescription for highly active antiretroviral therapy medications."
Read the rest of the article here.
All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.
Doctor's Guide
DGDispatch
By Ed Susman
SAN FRANCISCO -- February 22, 2010 -- Patients with HIV who begin antiretroviral therapy before their CD4-positive cell counts drop below 200 cells/mm3 appear to have significantly reduced risk of developing squamous cell cancer of the anus, researchers said here at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).
"Although the crude incidence of squamous cell cancer of the anus in HIV-infected individuals is higher among those who ever received highly active antiretroviral therapy [HAART], the risk of squamous cell cancer of the anus is significantly lower in patients with re-therapy nadir CD4 counts of 200 or less, and the risk decreases with higher adherence to therapy," said Elizabeth Chiao, MD, Baylor College of Medicine, Houston, Texas.
"Initiating highly active antiretroviral therapy at higher CD4 counts and optimising adherence may decrease the risk of subsequent squamous cell cancer of the anus," she said during her poster presentation on February 19.
Dr. Chiao and colleagues performed a retrospective cohort study utilising data from the Veterans Affairs Immunologic Case Registry from 1987 to 2007, which contains laboratory and pharmacy data, as well as ICD-9 diagnosis codes of all HIV-positive veterans.
"We identified 36,788 individuals in the cohort," she said. "Of these, 20,085 received at least 1 prescription for highly active antiretroviral therapy medications."
Read the rest of the article here.
All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.
Total Comments 0
Comments
Recent Blog Entries by admin
- Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand (07-29-2010)
- Potential Biomarkers of VELCADE Activity in Patients w/Relapsed Mantle Cell Lymphoma (07-29-2010)
- UT Health Science Center team finds adrenal cancer gene (07-29-2010)
- £50m boost to help cancer patients (07-29-2010)
- Generic Gemzar may appear soon (07-29-2010)
